Mink therapeutics announces virtual annual shareholders meeting

New york, june 05, 2024 (globe newswire) -- mink therapeutics, inc. (nasdaq: inkt), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer t (inkt) cell therapies to treat cancer and other immune-mediated diseases, today announced that its annual shareholders meeting will begin at 9:30 a.m. et. on june 12, 2024, and will be conducted in a virtual format only. registration for attendees will start at 9:15 a.m. et.
INKT Ratings Summary
INKT Quant Ranking